Krzysztof Moroz, M.D.

Professor, Vice Chair for Clinical Services, Co-Director, Biospecimen Core, LCRC

Director, Cytology Laboratory and Cytopathology Fellowship Program, Tulane Cancer Center Member - Translational Oncology Research Program
Phone
504-988-5224
School of Medicine
Department
Pathology Laboratory Medicine
Tulane Cancer Center
Krzysztof Moroz, MD

Education & Affiliations

M.D., Academy of Medicine, Bialystok, Poland, 1984
Anatomic Pathology, Mallory Institute of Pathology, Boston University School of Medicine, Boston MA, 1989-1991
Clinical Pathology, University Hospital, Boston University School of Medicine, Boston, MA, 1991-1993
Fellowship, Cytopathology, Mallory Institute of Pathology, Boston University School of Medicine, Boston, MA, 1993-1994

Biography

Dr. Moroz received his MD from the Academy of Medicine in Bialystok, Poland. He completed his anatomic pathology training at the Mallory Institute of Pathology, Boston University School of Medicine in Boston, followed by clinical pathology training at the University Hospital at Boston University School of Medicine. Dr. Moroz completed fellowship training in cytopathology at the Mallory Institute of Pathology at Boston University School of Medicine in 1994. He is board-certified in anatomic and clinical pathology (1993) and cytopathology (1994) by the American Board of Pathology. He is a fellow of the College of American Pathologists. Dr. Moroz joined Tulane University School of Medicine in 1994. He is actively participating in the cytopathology and surgical pathology services of the department. His research interests include breast and prostate cancer, and prognostic tumor markers. He is co-directing the Biospecimen Core Laboratory of the Louisiana Cancer Research Consortium.

Specialty Certifications

1993, American Board of Pathology, Anatomic and Clinical Pathology

1994, American Board of Pathology, Cytopathology

Contributions

Liu S, Liu F, Zhang B, Yan P, Rowan BG, Mageed AB, Steele C, Jazwinski SM, Moroz K, Wung A, Myers L, Sartor O, Zhang Q. CD4+ T helper 17 cell response of aged mice promotes prostate cancer cell migration and invasion. The Prostate, 01 May 2020, DOI: 10.1002/pros.23990

 

Yadav S, Anbalagan M, Baddoo M, Chellamuthu VK, Mukhopadhyay S, Woods C, Jiang W, Moroz K, Flemington EK, Makridakis N. Somatic mutations in the DNA repairome in prostate cancers in African Americans and Caucasians. Oncogene (2020) Apr 16. doi: 10.1038/s41388-020-1280-x. PMID: 32300177

 

Dash S, Aydin Y, Moroz K. Chaperone-Mediated Autophagy in the Liver: Good or Bad? Cells. 2019 Oct 24;8(11). pii: E1308. doi: 10.3390/cells8111308. PMID: 31652893

 

Falk NK, Ratnayaka S, Sholl AB, Moroz K, Kalinicheva T. Cytologic, histologic and molecular findings of papillary thyroid carcinoma variants, one institution’s experience. Journal of Solid Tumors. 2019, Vol. 9, No. 2. DOI: 10.5430/jst.v9n2p32.

 

Matossian MD, Burks HE, Elliott S, Hoang VT, Bowles AC, Sabol RA, Wahba B, Anbalagan M, Rowan B, Abazeed ME, Bunnell BA, Moroz K, Miele L, Rhodes LV, Jones SD, Martin EC, Collins-Burow BM, Burow ME. Drug resistance profiling of a new triple negative breast cancer patient-derived xenograft model. BMC Cancer. 2019 Mar 7;19(1):205. doi: 10.1186/s12885-019-5401-2. PMID: 30845999

 

Matossian MD, Burks HE, Bowles AC, Elliott S, Hoang VT, Sabol RA, Pashos NC, O'Donnell B, Miller KS, Wahba BM, Bunnell BA, Moroz K, Zea AH, Jones SD, Ochoa AC, Al-Khami AA, Hossain F, Riker AI, Rhodes LV, Martin EC, Miele L, Burow ME, Collins-Burow BM. A novel patient-derived xenograft model for claudin-low triple-negative breast cancer. Breast Cancer Res Treat. 2018 Jun;169(2):381-390. doi: 10.1007/s10549-018-4685-2. Epub 2018 Feb 1. PMID: 29392581

 

Edwards DR, Moroz K, Zhang H, Mulholland D, Abdel-Mageed AB, Mondal D. PRL‑3 increases the aggressive phenotype of prostate cancer cells in vitro and its expression correlates with high-grade prostate tumors in patients. Int J Oncol. 2018 Feb;52(2):402-412. doi: 10.3892/ijo.2017.4208. Epub 2017 Nov 20. PMID: 29207031

 

Aydin Y, Chedid M, Chava S, Danielle Williams D, Liu S, Hagedorn CH, Sumitran-Holgersson S, Reiss K, Moroz K, Lu H, Balart LA, Dash S. Activation of PERK-Nrf2 oncogenic signaling promotes Mdm2-mediated Rb degradation in persistently infected HCV culture. Sci Rep. 2017 Aug 23;7(1):9223. doi: 10.1038/s41598-017-10087-6.

 

Chava S, Lee C, Aydin Y, Chandra PK, Dash A, Chedid M, Thung SN, Moroz K, Wu T, Nayak NC, Dash S. Chaperone-mediated autophagy compensates for impaired macroautophagy in the cirrhotic liver to promote hepatocellular carcinoma. Oncotarget. 2017 Jun 20;8(25):40019-40036. doi: 10.18632/oncotarget.16685.

 

Moustafa AA, Ziada M, Elshaikh A, Datta A, Kim H, Moroz K, Srivastav S, Thomas R, Silberstein JL, Moparty K, Salem FE, El-Habit OH, Abdel-Mageed AB. Identification of microRNA signature and potential pathway targets in prostate cancer. Exp Biol Med (Maywood). 2017 Mar;242(5):536-546. doi: 10.1177/1535370216681554. Epub 2016 Dec 8.

 

Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, Boulares AH, Friedlander P, Miccoli P, Kandil E. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery. 2017 Apr;161(4):1122-1128. doi: 10.1016/j.surg.2016.06.081. Epub 2016 Dec 2.

 

Al-Qurayshi Z, Deniwar A, Thethi T, Mallik T, Srivastav S, Murad F, Bhatia P, Moroz K, Sholl AB, Kandil E. Association of Malignancy Prevalence with Test Properties and Performance of the Gene Expression Classifier in Indeterminate Thyroid Nodules. JAMA Otolaryngol Head Neck Surg. 2016 Dec 15. doi: 10.1001/jamaoto.2016.3526. PMID:27978562

 

Seijo E, Lima D, Iriabho E, Almeida J, Monico J, Echeverri M, Gutierrez S, Flores I, Lee JH, Fisher K, Grizzle WE, Sica GL, Butler C, Hicks C, Meade CD, Sodeke SO, Moroz K, Coppola D, Munoz-Antonia T. Construction and Validation of a Multi-Institutional Tissue Microarray of Invasive Ductal Carcinoma from Racially and Ethnically Diverse Populations. Cancer Control. 2016 Oct;23(4):383-389.

 

Zhang J, Baddoo M, Han C, Strong MJ, Cvitanovic J, Moroz K, Dash S, Flemington EK, Wu T. Gene network analysis reveals a novel 22-gene signature of carbon metabolism in hepatocellular carcinoma. Oncotarget. 2016 Aug 2;7(31):49232-49245. doi: 10.18632/oncotarget.10249.

 

Deniwar A, Hammad AY, Ali DB, Alsaleh N, Lahlouh M, Sholl AB, Moroz K, Aslam R, Thethi T, Kandil E, MD. Optimal Timing for a Repeat FNA Biopsy of Thyroid Nodule Following an Initial Non-Diagnostic FNA. The American Journal of Surgery. doi:10.1016/j.amjsurg.2016.04.010

 

Doucet ME, Bloomhardt HM, Moroz K, Lindhurst MJ, Biesecker LG. Lack of mutation-histopathology correlation in a patient with Proteus syndrome. Am Am J Med Genet A. 2016 Jun;170(6):1422-1432. doi: 10.1002/ajmg.a.37612. Epub 2016 Apr 26.

Cytopathology and Surgical Pathology

Breast Cancer Pathology

GU/GYN Pathology

Prognostic Tumor Markers